Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Chronic Rhinosinusitis With Nasal Polyposis
NCT05369039Phase 2Unknown
- Sponsor
- Menoufia University
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of roflumilast in chronic rhinosinusitis with nasal polyposis (CRSwNP) (2 arms), sponsored by Menoufia University. Primary endpoints: Sino-Nasal Outcome Test-22 at 2 weeks, Lund Kennedy Score at 2 weeks and 2 more. Status: unknown.
02
Drugs
roflumilast
03
Conditions
chronic rhinosinusitis with nasal polyposis (CRSwNP)
Beyond the preview
Go deeper on NCT05369039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369039.